Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

FGF23 modifies the relationship between vitamin D and cardiac remodeling.

Ky B, Shults J, Keane MG, Sutton MS, Wolf M, Feldman HI, Reese PP, Anderson CA, Townsend RR, Deo R, Lo J, Gadegbeku C, Carlow D, Sulik MJ, Leonard MB; CRIC Study Investigators.

Circ Heart Fail. 2013 Jul;6(4):817-24. doi: 10.1161/CIRCHEARTFAILURE.112.000105. Epub 2013 Jun 7.

2.

Relationship between vitamin D status and left ventricular geometry in a healthy population: results from the Baltimore Longitudinal Study of Aging.

Ameri P, Canepa M, Milaneschi Y, Spallarossa P, Leoncini G, Giallauria F, Strait JB, Lakatta EG, Brunelli C, Murialdo G, Ferrucci L.

J Intern Med. 2013 Mar;273(3):253-62. doi: 10.1111/joim.12007. Epub 2012 Nov 12.

3.

Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites.

Dai B, David V, Alshayeb HM, Showkat A, Gyamlani G, Horst RL, Wall BM, Quarles LD.

Kidney Int. 2012 Nov;82(10):1061-70. doi: 10.1038/ki.2012.222. Epub 2012 Jun 27.

4.

The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.

Taal MW, Thurston V, McIntyre NJ, Fluck RJ, McIntyre CW.

Kidney Int. 2014 Aug;86(2):407-13. doi: 10.1038/ki.2013.537. Epub 2014 Jan 15.

PMID:
24429404
5.

Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.

Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H.

Clin J Am Soc Nephrol. 2012 May;7(5):810-9. doi: 10.2215/CJN.08680811. Epub 2012 Feb 23.

6.

Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.

Taylor EN, Hoofnagle AN, Curhan GC.

Clin J Am Soc Nephrol. 2015 Apr 7;10(4):667-75. doi: 10.2215/CJN.07060714. Epub 2015 Jan 26.

7.

Fibroblast growth factor 23, vitamin D, and health disparities among African Americans with chronic kidney disease.

Saxena N, Gutiérrez OM.

Semin Nephrol. 2013 Sep;33(5):448-56. doi: 10.1016/j.semnephrol.2013.07.006. Review.

8.

Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Quarles LD.

Exp Cell Res. 2012 May 15;318(9):1040-8. doi: 10.1016/j.yexcr.2012.02.027. Epub 2012 Mar 7. Review.

9.
10.

Vitamin D bioavailability and catabolism in pediatric chronic kidney disease.

Denburg MR, Kalkwarf HJ, de Boer IH, Hewison M, Shults J, Zemel BS, Stokes D, Foerster D, Laskin B, Ramirez A, Leonard MB.

Pediatr Nephrol. 2013 Sep;28(9):1843-53. doi: 10.1007/s00467-013-2493-9. Epub 2013 Jun 2.

11.

Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.

Wan M, Smith C, Shah V, Gullet A, Wells D, Rees L, Shroff R.

Nephrol Dial Transplant. 2013 Jan;28(1):153-61. doi: 10.1093/ndt/gfs411. Epub 2012 Nov 23.

PMID:
23180879
12.

Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D.

Nguyen-Yamamoto L, Karaplis AC, St-Arnaud R, Goltzman D.

J Am Soc Nephrol. 2017 Feb;28(2):586-597. doi: 10.1681/ASN.2016010066. Epub 2016 Aug 17.

PMID:
27535551
13.

Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study.

Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK.

J Am Soc Nephrol. 2016 Jan;27(1):227-37. doi: 10.1681/ASN.2014101009. Epub 2015 May 13.

15.

FGF23 is associated with disease severity and prognosis in chronic heart failure.

Poelzl G, Trenkler C, Kliebhan J, Wuertinger P, Seger C, Kaser S, Mayer G, Pirklbauer M, Ulmer H, Griesmacher A.

Eur J Clin Invest. 2014 Dec;44(12):1150-8. doi: 10.1111/eci.12349. Epub 2014 Nov 3.

PMID:
25294008
16.

[Mineral metabolism in patients on chronic peritoneal dialysis].

Ceballos O ML, Rojo L A, Azócar P M, Ibacache M MJ, Delucchi B A, Quiroz Z L, Irarrázabal M C, Delgado B I, Ugarte P F, Cano Sch F.

Rev Chil Pediatr. 2014 Feb;85(1):31-9. doi: 10.4067/S0370-41062014000100004. Spanish.

17.

FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.

Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG.

J Clin Endocrinol Metab. 2009 Jul;94(7):2332-7. doi: 10.1210/jc.2008-2396. Epub 2009 Apr 14.

PMID:
19366850
18.

Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.

Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.

Nephrol Dial Transplant. 2013 Feb;28(2):352-9. doi: 10.1093/ndt/gfs460. Epub 2012 Nov 4.

19.

Serum 25-hydroxyvitamin D and left ventricular systolic function in a non-smoking population: the Tromsø Study.

Kamycheva E, Wilsgaard T, Schirmer H, Jorde R.

Eur J Heart Fail. 2013 May;15(5):490-5. doi: 10.1093/eurjhf/hfs210. Epub 2013 Jan 15.

20.

Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.

Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, Larsson TE.

Clin J Am Soc Nephrol. 2013 May;8(5):781-6. doi: 10.2215/CJN.09570912. Epub 2013 Jan 18.

Supplemental Content

Support Center